Patent, Original, and Generic Drugs Explained: Cost, Efficacy & Differences

Patent Drugs

“Years of silent effort, sky-high prices once on the market”

Patent drugs, also called patented protected drugs, refer to those drugs holding patents. Patent protection is an exclusive protection measure for innovative drugs. Through patent protection, pharmaceutical companies can enjoy exclusive sales rights for a certain period.

Patent drugs are the earliest researched and patented branded drugs. From initial research to final market launch, it often consumes vast amounts of time, manpower, and resources. 

During the patent period (usually 20 years, but after subtracting R&D and approval time, actual market exclusivity lasts about 8–12 years), only this company can legally produce and sell the drug; others cannot copy it.

Why are patent drugs expensive?

• Screening compounds costs money: Developing a patent drug starts with screening thousands of compounds. Researchers use various experiments and techniques to find compounds with potential medicinal value. This process may take years.
• Experiments cost money: After identifying potentially active compounds, preclinical studies begin. This stage, done in labs and animals, assesses drug safety, efficacy, and pharmacological properties. It includes toxicology (toxicity in animals and safe dosage), pharmacokinetics (absorption, distribution, metabolism, and excretion), and pharmacodynamics (therapeutic effects on disease models). Preclinical studies usually take 2–5 years.
• Clinical trials cost money: Clinical trials are key, generally divided into Phase I, II, III, and IV. Phase I trials, in healthy volunteers (20–100 people, several months to a year), assess safety and dose range. Phase II trials, in patients with the target disease (100–500 patients, 1–2 years), further evaluate efficacy and safety. Phase III trials are large multi-center studies (hundreds to thousands of patients, 2–3 years or longer) to confirm efficacy and safety for market approval. Phase IV trials happen after marketing to monitor safety and long-term effects in broad populations, lasting years or decades.
• Regulatory approval costs money: After trials, companies submit a New Drug Application (NDA) to regulatory authorities who thoroughly review clinical data, manufacturing processes, quality control, etc. Only after approval can the drug be marketed. Even post-approval, strict monitoring continues with regular safety and efficacy reports required.

Thus, the “sky-high” price of patent drugs not only covers the cost of the successful drug but also spreads the costs of numerous failed drug candidates. It’s the “tuition fee” that supports future innovation.

Original Drugs

“Once exclusive, now common to all”

After the patent protection period ends, drugs produced by the original manufacturer are called original drugs.

Original drugs refer to new drugs already in clinical use, approved after screening thousands of compounds and strict clinical trials. They have comprehensive safety and efficacy data as their basis and follow strict regulations and standards in R&D, ensuring high quality and efficacy.

Relation to patent drugs: During patent protection, an original drug is a patent drug. Once the patent expires, if the original manufacturer continues production, the drug is called an original drug.

The core difference lies in patent status: patent drugs have market exclusivity during patent periods; original drugs compete with generics after patent expiration.

Advantages recognized:

• R&D and clinical data accumulation: Original drug development is long and strict, usually 10–15 years or longer. This process accumulates rich clinical data on efficacy, safety, and adverse reactions, providing reliable evidence for clinical use and high market recognition.
• Quality control and manufacturing: Original drugs often have strict quality standards and advanced technology. Original manufacturers usually have their own R&D and production facilities for strict control and management, ensuring purity, impurity control, and stability. This manufacturing advantage translates into better quality and efficacy, attracting doctors and patients.
• Price and market competition: Though patent protection is over, original drugs retain market competitiveness due to brand effect, clinical data, and quality advantages. Prices are usually higher than generics. However, with generics flooding the market, original drug prices may face pressure, sometimes dropping 30%–50% in some regions after generic launches. Overall, original drugs remain more expensive than generics but no longer outrageously so.

Generic Drugs

“Affordable substitutes”

After patent expiration, other manufacturers can produce generic drugs that must pass equivalence evaluation. They must have basically the same active ingredients, dose, safety, and efficacy as original drugs to be marketed.

Generics only replicate the original drug’s main molecular structure and match in dosage form, safety, efficacy, administration route, quality, performance, and intended use.

Why cheaper? Because they “copy”

Compared to patent and original drugs, generics save time, money, and effort. They don’t require early compound screening or large clinical trials. Generic R&D cycles are typically 2–3 years, costing a few million USD, about 1%–5% of original drug R&D costs. This cost advantage makes generics much more affordable for patients.

Pros and cons: Pros—affordable. Cons—manufacturing differences may cause variation in impurity profiles, leading to occasional therapeutic effect fluctuations when switching for some patients. In China, full equivalence evaluation started only in 2016; earlier generics had mixed quality, causing patient concerns. Drugs with narrow therapeutic windows (e.g., warfarin, carbamazepine) require extra caution when switching.

Common Patient Questions

1. “Will generics be ineffective?” Generics passing national equivalence evaluations are proven equivalent in efficacy and safety to original drugs. Individual differences exist; if after switching blood pressure, blood sugar, or lipid control worsens, inform your doctor promptly.
2. “Why do hospitals sometimes prescribe only original drugs?” This depends on insurance formularies, hospital procurement results (e.g., national centralized procurement winning products), hospital stock, and other factors. Patients can buy alternatives outside hospitals with prescriptions but should consult doctors first.
3. “Are imported generics always better than domestic ones?” Not necessarily. Leading domestic companies’ generics passing equivalence evaluations are equally reliable. Domestic drugs may have local advantages in logistics, cold chain, and after-sales tracking. The key is whether they pass equivalence evaluation.
4. “How to tell if my drug is original or generic?” Check the brand name and manufacturer. Original drugs usually have catchy brand names and indicate “Original” on the box. Generics have diverse brand names but display a “Generic Drug Equivalence Evaluation Passed” blue label. If unsure, scan the drug’s traceability code with your phone to check origin.

There is no absolute good or bad, only suitability. In the world of drugs, there are no “miracle cures,” only “choices.”

• Patent drugs are the pioneers; without them, no new drugs.
• Original drugs have a solid foundation and stable quality.
• Generics make good medicines affordable for everyone.

Doctors consider disease, economics, insurance, and accessibility to provide the “most suitable” treatment. Patients should communicate with doctors, avoid blindly chasing expensive drugs or cheap ones. May we all achieve the greatest health benefit with the smallest economic burden.